Galmed Pharmaceuticals (GLMD) PT Lowered to $6 at Maxim Group, Following Earnings
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Price: $0.36 --0%
Rating Summary:
6 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
6 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy lowered the price target on Galmed Pharmaceuticals (NASDAQ: GLMD) to $6.00 (from $10.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
- Goldman Sachs Upgrades Bank Central Asia Tbk (BBCA:IJ) (PBCRY) to Buy
- Northern Star Resources (NST:AU) (NESRF) PT Lowered to AUD19.15 at Canaccord Genuity
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Maxim Group, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
